HomeCompareTYIDF vs ABBV

TYIDF vs ABBV: Dividend Comparison 2026

TYIDF yields 1.53% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $80.5K in total portfolio value
10 years
TYIDF
TYIDF
● Live price
1.53%
Share price
$127.50
Annual div
$1.95
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$168.66
Full TYIDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TYIDF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTYIDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TYIDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TYIDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TYIDF
Annual income on $10K today (after 15% tax)
$129.85/yr
After 10yr DRIP, annual income (after tax)
$143.36/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,912.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TYIDF + ABBV for your $10,000?

TYIDF: 50%ABBV: 50%
100% ABBV50/50100% TYIDF
Portfolio after 10yr
$62.1K
Annual income
$12,470.21/yr
Blended yield
20.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TYIDF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.6
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TYIDF buys
0
ABBV buys
0
No recent congressional trades found for TYIDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTYIDFABBV
Forward yield1.53%3.06%
Annual dividend / share$1.95$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$21.9K$102.3K
Annual income after 10y$168.66$24,771.77
Total dividends collected$1.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: TYIDF vs ABBV ($10,000, DRIP)

YearTYIDF PortfolioTYIDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,853$152.77$11,550$430.00$697.00ABBV
2$11,767$154.95$13,472$627.96$1.7KABBV
3$12,748$157.02$15,906$926.08$3.2KABBV
4$13,799$158.98$19,071$1,382.55$5.3KABBV
5$14,926$160.83$23,302$2,095.81$8.4KABBV
6$16,134$162.58$29,150$3,237.93$13.0KABBV
7$17,427$164.23$37,536$5,121.41$20.1KABBV
8$18,813$165.80$50,079$8,338.38$31.3KABBV
9$20,297$167.27$69,753$14,065.80$49.5KABBV
10$21,887$168.66$102,337$24,771.77$80.5KABBV

TYIDF vs ABBV: Complete Analysis 2026

TYIDFStock

Toyota Industries Corporation manufactures and sells automobiles, material handling equipment, textile machinery, and others in Japan and internationally. The company operates through Automobile, Materials Handling Equipment, and Textile Machinery segments. It provides vehicles; gas, gasoline, and diesel engines for automobiles, industrial equipment, turbochargers, and foundry parts; car air-conditioning compressors; car electronics comprising DC-DC converters, rear inverters, direct-cooling devices, DC-AC inverters, and charging systems; and stamping dies consists of automotive and lift truck stamping dies. The company also offers counterbalanced lift trucks, electric reach trucks, skid steer loaders, tow tractors, and electric tow tractors; stationary/fixed type racks, nesting pallets, mobile racks, and automated storage and retrieval systems; automatic guided vehicle systems, high speed rail guided vehicle systems, and automatic guided lift and pallet trucks. In addition, it provides spinning machines consisting of ring spinning and roving frames; weaving machinery; and cotton classing and yarn testing instruments, as well as leases materials handling systems and industrial equipment. Further, the company offers aerial work platforms; in-house transporters; software; and funding, loan, and other financial services. Additionally, it is involved in the operation of sports facility and nursing homes; real estate leasing; trucking, warehousing, distribution consulting; building management, construction, and real estate; travel agency, renovation, sale of tube amplifiers, and organizing and running of events; personnel placement, contract office staffing, and patent investigation; management and operation of employee clubs and restaurant management; administrative processing for payroll accounting; and contract manufacturing of electronic devices, as well as sale of hardware. The company was incorporated in 1926 and is headquartered in Kariya, Japan.

Full TYIDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TYIDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TYIDF vs SCHDTYIDF vs JEPITYIDF vs OTYIDF vs KOTYIDF vs MAINTYIDF vs JNJTYIDF vs MRKTYIDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.